<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03056222</url>
  </required_header>
  <id_info>
    <org_study_id>CF2 Rev.1 IMP</org_study_id>
    <nct_id>NCT03056222</nct_id>
  </id_info>
  <brief_title>CardioFocus vs. Contact Force Guided Pulmonary Vein Isolation in Paroxysmal Atrial Fibrillation</brief_title>
  <acronym>CF²</acronym>
  <official_title>CardioFocus vs. Contact Force Guided Pulmonary Vein Isolation in Paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I-Med-Pro GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I-Med-Pro GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the acute procedure and safety outcomes as well as long&#xD;
      term clinical outcomes of 2 groups of patients treated with the HeartLight® Endoscopically&#xD;
      Guided Laser Ablation (EGLA) or a commercially available Contact Force Sensing Irrigated&#xD;
      Radiofrequency (RF) Ablation Catheter plus, at the operator's discretion, 3D&#xD;
      Electroanatomical Mapping (EAM) for the treatment of Paroxysmal Atrial Fibrillation (PAF).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 10, 2017</start_date>
  <completion_date type="Actual">November 15, 2021</completion_date>
  <primary_completion_date type="Actual">August 16, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from symptomatic, recurrent atrial fibrillation (AF) off of anti-arrhythmic drugs</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>Recurrent AF is defined as any documented episode of AF lasting more than 30 seconds after a blanking period of 90 days post procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute procedure success</measure>
    <time_frame>30 minutes post procedure</time_frame>
    <description>Confirmation of electrical isolation with a circular mapping catheter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure and fluoroscopy time</measure>
    <time_frame>During procedure</time_frame>
    <description>Time will be taken</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of peri-procedural complications</measure>
    <time_frame>From procedure to 12 months post procedure</time_frame>
    <description>E.g. major bleeding requiring intervention, phrenic nerve palsy, pericardial tamponade, thrombo-embolic events, pulmonary vein (PV) -stenosis, atrial-to-esophageal fistula, death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from symptomatic, recurrent Atrial Tachy Arrhythmia (ATA) off of anti-arrhythmic drugs</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>Recurrent ATA is defined as any documented episode of ATA lasting more than 30 seconds after a blanking period of 90 days post procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>HeartLight® EGLA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be treated with the endoscopically guided laser ablation catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Contact Force Sensing Irrigated RF ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be treated with a contact force sensing irrigated radiofrequency ablation catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ablation catheter</intervention_name>
    <description>Ablation of paroxysmal atrial fibrillation</description>
    <arm_group_label>Contact Force Sensing Irrigated RF ablation</arm_group_label>
    <arm_group_label>HeartLight® EGLA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must not have undergone a previous ablation for the treatment of PAF&#xD;
&#xD;
          -  AF Type - Diagnosed with symptomatic paroxysmal atrial fibrillation (PAF) where PAF is&#xD;
             defined as recurrent (two or more) episodes of AF that terminate spontaneously in less&#xD;
             than seven days, usually less than 48 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Atrial fibrillation secondary to a reversible cause or of non-cardiac origin&#xD;
&#xD;
          -  Diagnosed with persistent atrial fibrillation defined as recurrent episodes lasting&#xD;
             more than 7 and less than 365 days&#xD;
&#xD;
          -  More than 4 electrical cardioversions in the year prior to enrollment but not&#xD;
             including cardioversions performed within 48 hours of arrhythmia onset&#xD;
&#xD;
          -  Documented left atrial thrombus on imaging&#xD;
&#xD;
          -  Cannot be removed from anti-arrhythmic drugs for other reasons than atrial&#xD;
             fibrillation&#xD;
&#xD;
          -  New York Heart Association (NYHA) functional Class III or Class IV heart failure&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 30%&#xD;
&#xD;
          -  Left atrial size &gt; 55 mm as measured in the parasternal antero-posterior view&#xD;
&#xD;
          -  Myocardial infarction within 60 days prior to enrolment&#xD;
&#xD;
          -  Woman of childbearing potential who is pregnant, lactating or not using adequate birth&#xD;
             control&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Metzner, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitäres Herz- und Gefäßzentrum UKE Hamburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hartcentrum OLV Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartcentrum Hasselt Jessa Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Homolce</name>
      <address>
        <city>Prague</city>
        <zip>15030</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isar Herz Zentrum</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>80331</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vinzenz Hospital Köln</name>
      <address>
        <city>Köln</city>
        <state>NRW</state>
        <zip>50733</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKSH, Universitäres Herzzentrum</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Am Urban</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäres Herz- und Gefäßzentrum UKE Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blackpool Victoria Hospital</name>
      <address>
        <city>Blackpool</city>
        <zip>FY3 8NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 14, 2017</study_first_submitted>
  <study_first_submitted_qc>February 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2017</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

